Financing

Proceeds from issuance of common stock relating to employee stock plans

Revolution Medicines, Inc. Proceeds from issuance of common stock relating to employee stock plans increased by 194.5% to $12.21M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1270.3%, from $891.00K to $12.21M. Over 3 years (FY 2021 to FY 2024), Proceeds from issuance of common stock relating to employee stock plans shows an upward trend with a 102.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026

How to read this metric

Higher proceeds generally correlate with higher employee participation in equity plans and can indicate positive sentiment regarding the company's long-term stock performance.

Detailed definition

Cash inflows resulting from the exercise of employee stock options or purchases through employee stock purchase plans. T...

Peer comparison

Standard for most publicly traded companies with equity-based compensation programs.

Metric ID: financing_proceeds_from_stock_plans

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$257.00K$319.00K$356.00K$305.00K$190.00K$209.00K$777.00K$499.00K$468.00K$1.01M$1.34M$810.00K$4.34M$3.00M$4.18M$891.00K$1.94M$4.15M$12.21M
QoQ Change+24.1%+11.6%-14.3%-37.7%+10.0%+271.8%-35.8%-6.2%+116.0%+32.3%-39.5%+435.8%-30.9%+39.3%-78.7%+117.4%+114.0%+194.5%
YoY Change-26.1%-34.5%+118.3%+63.6%+146.3%+383.7%+72.2%+62.3%+827.4%+196.8%+212.3%+10.0%-55.4%+38.1%>999%
Range$190.00K$12.21M
CAGR+135.8%
Avg YoY Growth+219.0%
Median YoY Growth+72.2%
Current Streak3 quarters growth

Frequently Asked Questions

What is Revolution Medicines, Inc.'s proceeds from issuance of common stock relating to employee stock plans?
Revolution Medicines, Inc. (RVMD) reported proceeds from issuance of common stock relating to employee stock plans of $12.21M in Q1 2026.
How has Revolution Medicines, Inc.'s proceeds from issuance of common stock relating to employee stock plans changed year-over-year?
Revolution Medicines, Inc.'s proceeds from issuance of common stock relating to employee stock plans increased by 1270.3% year-over-year, from $891.00K to $12.21M.
What is the long-term trend for Revolution Medicines, Inc.'s proceeds from issuance of common stock relating to employee stock plans?
Over 3 years (2021 to 2024), Revolution Medicines, Inc.'s proceeds from issuance of common stock relating to employee stock plans has grown at a 102.4% compound annual growth rate (CAGR), from $1.49M to $12.33M.
What does proceeds from issuance of common stock relating to employee stock plans mean?
Cash received from employees exercising stock options or buying company shares.